Perceptions of Safety: Marijuana Smoke vs Tobacco Smoke

Aug.16.2023
Perceptions of Safety: Marijuana Smoke vs Tobacco Smoke
A recent study published in JAMA Network Open reveals that a majority of Americans believe marijuana smoke is safer than tobacco smoke.

Special statement: We would like to make it clear that the information provided in this article is trustworthy and accurate. Our team has conducted thorough research and verification to ensure the reliability of the facts presented. We aim to provide our readers with reliable news and unbiased reporting, upholding professional standards in journalism.


This article is solely intended for industry research and communication among professionals and does not involve any product evaluation or recommendation.


Please note that the items mentioned in the article may be subject to different regulatory policies in different countries and regions. Readers are advised to strictly adhere to relevant laws and regulations in China.


This article is intended for readers who are 18 years of age or older.


On August 14, according to a report by CNN, a survey from the Journal of the American Medical Association Network Open revealed that the majority of respondents (44%) believe that smoking marijuana is safer than smoking tobacco. Additionally, they also believe that the risks of inhaling secondhand marijuana smoke for both adults and children are lower than those of cigarette smoke. However, Dr. Beth Cohen, the lead author of the study and a medical professor at the University of California, San Francisco (UCSF), as well as the co-director of the UCSF Inpatient Investigative Methods and Epidemiology Program, argues that these beliefs are not accurate.


A study published in the Journal of the American Medical Association Network Open examined the growing acceptance of marijuana among a sample of over 5,000 individuals with an average age of 50. The study aimed to understand their attitudes towards the safety of marijuana use compared to tobacco use. Participants were also asked whether they believed secondhand smoke from marijuana or tobacco could be harmful.


According to a study conducted in 2017, 2020, and 2021, the positive perception of marijuana among people has been steadily increasing. By the final year of the survey in 2021, over 44% of respondents believed that marijuana was somewhat or even safer, while only 25.5% considered cigarettes to be safer.


In light of the potential harm it may cause to others (secondhand smoke), over 40% of individuals consider marijuana smoke to be safer, while only 23% opt for tobacco.


However, experts in the field do not agree with this trend. Carol Boyd, the founding director of the Center for Drug, Alcohol, Smoking, and Health Research at the University of Michigan-Ann Arbor, stated that marijuana smoke contains "a significant amount of toxins and tar," which could potentially harm the lungs.


Boyd stated:


I am unable to comment on the dangers, but if an individual is in a confined space with marijuana users, the presence of marijuana components may be detected in their urine. They may also experience other physiological effects of marijuana, including increased heart rate and a sense of excitement.


Boyd believes that comparing the health risks of consuming marijuana and tobacco is of little significance. All forms of smoking have irritating effects on the respiratory system, he commented.


In an era where humanity breathes polluted air, being smoke-free is beneficial.


Research on marijuana has been hampered by its illegal status in many states across the United States (currently still the case). Furthermore, the federal government has historically imposed strict regulations on the study of marijuana. These factors have posed significant challenges to the investigation of marijuana use.


With an increasing number of states legalizing marijuana for recreational use, researchers are now delving further into exploring the consequences of long-term cannabis consumption.


However, the current research shows that marijuana cigarettes indeed have some advantages compared to regular cigarettes, Boyd further explained.


It is commonly believed that frequent marijuana consumption is associated with chronic bronchitis, pharyngitis, and bronchial inflammation. Despite the presence of carcinogens in marijuana smoke, such as benzopyrene and benzanthracene, it seems that smoking marijuana does not appear to cause lung cancer.


In addition, individuals who consume marijuana tend to take deep breaths and hold the smoke in their lungs for extended periods of time. According to the American Lung Association, this can "result in increased exposure to tar with each breath.


Consuming marijuana can impair the lungs' first line of defense against infection, killing cells that help remove dust and bacteria, and leading to increased mucus formation.


The American Lung Association has stated that the consumption of marijuana can also suppress the immune system and potentially expose users to a particular type of mold that can grow on cannabis.


While further research is needed to understand the impact of marijuana consumption on the lungs, as well as the health effects of second-hand marijuana smoke, Cohen asserts that the current knowledge is worrisome.


She said:


I am not opposed to marijuana; I simply hope that people can make informed decisions. Even if further research indicates that marijuana smoke is relatively less harmful compared to tobacco smoke, it does not necessarily mean that it is completely safe.


Reference: [1] A recent study reveals that a significant number of Americans hold a misconception regarding the safety of marijuana smoke compared to tobacco smoke.


Title: A Comparative Analysis: Public Perceptions of the Safety of Daily Cannabis and Tobacco Smoking, along with Secondhand Smoke Exposure (2017-2021) Public opinion on the safety of daily cannabis consumption and tobacco smoking, along with the potential risks associated with secondhand smoke exposure, has been examined between the years of 2017 and 2021.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Malaysia's Poisons Board Backs New Vape Nicotine Exemption After Unanimously Opposing 2023 Proposal
Malaysia's Poisons Board Backs New Vape Nicotine Exemption After Unanimously Opposing 2023 Proposal
Malaysia's Poisons Board has endorsed Health Minister Dzulkefly Ahmad's proposal to exempt liquid nicotine used in vaping products from the Poisons List, according to a November 2, 2026, report by CodeBlue. The Board unanimously opposed a similar proposal in 2023, but the government proceeded with the exemption. The Kuala Lumpur High Court invalidated the 2023 decision in May 2026, and the government withdrew its appeal in August. No new ministerial order has been published. The development raises questions about the interaction between Malaysia's two regulatory frameworks and the treatment of RM354.51 million in excise duties collected on e-cigarette and vape products between May 2023 and June 11, 2026.
Regulations
Nov.03
AIR Q3 Sales Rise 11%, but New Products Generate Just $2.1 Million in Nine Months as U.S. Vape Push Awaits FDA Review
AIR Q3 Sales Rise 11%, but New Products Generate Just $2.1 Million in Nine Months as U.S. Vape Push Awaits FDA Review
AIR Global PLC (NASDAQ: AIIR), a producer of flavored shisha tobacco and next-generation nicotine products, reported an 11.1% increase in third-quarter 2026 revenue to $99.8 million and a 7.7% rise in adjusted EBITDA to $30.9 million. Revenue for the first nine months increased 6.0% to $306.7 million, but the company posted a $74.2 million net loss, affected by listing-related expenses and other costs. Its New Growth Categories (NGC) business generated $2.1 million in nine-month revenue and an adjusted EBITDA loss of $10.8 million. AIR maintained its 2026 revenue growth guidance of 4%–6%, while lowering its capital expenditure outlook and raising its year-end leverage forecast from approximately 2.1 times to 2.5 times. The company has submitted a U.S. PMTA for its Crown Switch pod vape, with future contributions from new products dependent on regulatory progress and commercialization.
Capital Markets
Nov.13
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
The U.S. Food and Drug Administration has revised the rules under Import Alert 98-07 to incorporate its May 2026 enforcement-priority policy for certain electronic nicotine delivery systems marketed without premarket authorization. The alert continues to allow detention without physical examination, or DWPE, for ENDS lacking required marketing authorization, while directing field divisions to apply the May risk-based framework. When necessary, detention or refusal decisions must also undergo review by the FDA's Center for Tobacco Products. Products including PACHA and Vuse Pro have already emerged as industry examples of the May policy, although enforcement discretion does not constitute FDA marketing authorization.
News
Sep.28 by 2Firsts Perspectives
Beyond IQOS ILUMA, PMI Expands Lower-Priced BONDS Heated Tobacco Platform: Seven Markets Added in Q3, With Rollouts in Japan, Europe and North Africa
Beyond IQOS ILUMA, PMI Expands Lower-Priced BONDS Heated Tobacco Platform: Seven Markets Added in Q3, With Rollouts in Japan, Europe and North Africa
Philip Morris International (PMI) is expanding the international footprint of BONDS by IQOS, its lower-priced heated tobacco platform. The company's third-quarter 2026 SEC filing shows that BONDS devices and BLENDS tobacco sticks were available in 15 markets at the end of September, up from eight at the end of June. In November, PMI announced plans to extend sales from three to 17 Japanese prefectures and introduced BONDS in Spain and Morocco. The platform uses ROUNDHEAT external heating technology and proprietary tobacco sticks, separate from the IQOS ILUMA system. In Japan, BONDS retails for ¥2,980, approximately 25% below ILUMA i ONE, while BLENDS costs ¥570 per pack. PMI management says BONDS targets cigarette smokers who have not adopted heated tobacco. Separate sales and revenue figures remain undisclosed.
company
Nov.06
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
Turning Point Brands said Executive Chairman David E. Glazek will become CEO on October 1, replacing Graham Purdy, who is stepping down for personal reasons. The company narrowed its 2026 adjusted EBITDA outlook to $70 million-$80 million from $70 million-$90 million while maintaining Modern Oral gross sales guidance of $330 million-$350 million and net sales guidance of $260 million-$270 million. In the second quarter, Modern Oral net sales rose 128% to $68.4 million and accounted for 48% of company-wide net sales. Adjusted EBITDA fell 50% year over year. TPB shares closed about 10% lower on September 21.
Market
Sep.22 by 2Firsts Perspectives
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech launched IKE 2.0 on September 28, initially targeting nicotine products with a platform that combines user identity verification, product authentication, configurable policy controls and data analytics. Products can be authenticated through direct device integration or NFC smart tags. IKE Tech was formed with participation from Ispire's Aspire North America, Berify and Chemular, with Ispire currently holding a 40% interest. Its age-verification component PMTA was accepted by the FDA in 2025 and remains under review. The company did not disclose customer names, commercial deployment volumes, pricing or revenue tied to IKE 2.0.
News
Sep.29 by 2Firsts Perspectives